The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I, open-label dose-escalation trial of weekly (qw) BI 836880, a vascular endothelial growth factor (VEGF)/angiopoietin-2 (Ang-2)-blocking Nanobody, in patients (pts) with advanced/metastatic solid tumors.
 
Nicolas Isambert
Travel, Accommodations, Expenses - AstraZeneca; Celgene; MedImmune; Novartis; PharmaMar; Roche/Genentech
 
Elena Elez
No Relationships to Disclose
 
Sylvie Zanetta
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Ignacio Matos
No Relationships to Disclose
 
Serge Nazabadioko
Employment - Boehringer Ingelheim
 
Wenqiong Xue
Employment - Boehringer Ingelheim
 
Philippe Carrière
Employment - Boehringer Ingelheim
 
Josep Tabernero
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Genentech/Roche; Lilly; Merck Serono; MSD; Novartis; Roche; Sanofi; Symphony Evolution; Taiho Pharmaceutical